Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales
As Manufacturing Issues Continue
The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.
You may also be interested in...
After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.
Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.